Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study

Giarratano, Tommaso; Frezzini, Simona; Zanocco, M.; Giorgi, Carlo Alberto; Mioranza, Eleonora; Griguolo, Gaia; Falci, Cristina; Faggioni, Giovanni; Tasca, Giulia; Liso, Elisabetta Di; Vernaci, Grazia Maria; Menichetti, Alice; Mantiero, Mara; Grosso, D.; Guarneri, Valentina; Dieci, Maria Vittoria

doi:10.1111/tbj.13711

Cited by 24 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data on efficacy of scalp cooling is mainly from the adjuvant setting and also show that results may be less effective with anthracycline-containing regimens. [124][125][126][127][128] A meta-analysis showed favorable impact on OS by prolonging treatment until disease progression. 129 In this analysis, data from 4 studies involving 666 patients indicated that median OS was increased by 23% (95% CI, 9%-38%; P5.01) in women receiving longer durations of chemotherapy versus a limited number of cycles.…”

Section: Systemic Chemotherapy For Recurrent or Stage IV Diseasementioning

confidence: 99%

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Gradishar

Anderson

Abraham

et al. 2020

Journal of the National Comprehensive Cancer Network

1,039

602

View full text Add to dashboard Cite

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

show abstract

Section: Systemic Chemotherapy For Recurrent or Stage IV Diseasementioning

confidence: 99%

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Gradishar

Anderson

Abraham

et al. 2020

Journal of the National Comprehensive Cancer Network

1,039

602

View full text Add to dashboard Cite

show abstract

“…The other protocols were 69%, 43%, and 40% effective for paclitaxel + EC, TC, and EC + paclitaxel, respectively. Chills and headaches were the most reported adverse effects [20].…”

Section: Resultsmentioning

confidence: 99%

“…The operational principle is to fill the hypothermic caps with a glycol-based liquid that remains at low temperatures. The caps are connected to a circulator machine that moves the liquid inside it, allowing the patient to remain with the cap during the entire treatment period, without changing the device [6,16,[18][19][20]. In a different method, the cap is not attached to a machine but is cooled before its use and changed at a predetermined time to maintain temperature [21].…”

Section: Introductionmentioning

confidence: 99%

Scalp Cooling Impact in Alopecia of Patients Under Treatment for Breast Cancer—Literature Review

Wiethan

Sari

Ferreira

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Chemotherapy-induced alopecia is a common side effect of breast cancer therapies. Thus, the objective of this study was to carry out a bibliographic survey concerning the effectiveness of scalp cooling in alopecia of patients undergoing treatment for breast cancer. The search was conducted in the databases LILACS (Latin American and Caribbean Literature in Health Sciences), PubMed, Science Direct, Scopus, and Web of Science, by using "scalp cooling" AND "breast cancer" as search terms. Articles from the last 5 years were selected, which included cohort studies, case reports, and randomized studies. The final sample consisted of 16 publications. Data from the studies revealed that the use of hypothermic cap was effective in reducing alopecia. In addition, factors such as temperature and time of cap usage, dose and combination of medications, and hair care influenced in the reduction of hair loss. It was possible to observe that treatment schedules without anthracyclines were more responsive to the effects of scalp cooling, reducing hair loss. Therefore, this study gathered relevant information, showing that scalp cooling is effective and its use should be encouraged by health professionals.

show abstract

“…SC significantly reduces the risk of CIA from taxane-based and anthracycline-based chemotherapy regimens [8][9][10][11][12]. The majority of studies have been conducted in patients with early-stage breast cancer receiving neoadjuvant or adjuvant chemotherapy with curative intent [13,14]. However, one prospective trial and one large registry analysis performed in patients with breast, lung, prostate, gastrointestinal/colorectal, and female genital solid tumors demonstrated the potential for broader use, including in the palliative setting [15,16].…”

Section: Introductionmentioning

confidence: 99%

“…SC has minimal adverse events, is a generally well-tolerated intervention, and contributes to patient well-being [ 3 , 17 ]. The most common SC-related adverse events are grade 1 and include chills, “heavy head”, headache, pain (scalp, forehead, or sinus), nausea, dizziness, pruritus, and skin ulceration [ 9 , 12 , 13 ]. No serious adverse events have been reported from the device and participants find the SC device to be reasonably comfortable [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for Alopecia

et al. 2020

View full text Add to dashboard Cite

Scalp cooling (SC) is an effective and generally well-tolerated method for prevention of chemotherapy-induced alopecia (CIA). Initially studied in early-stage breast cancer, these devices have expanded US Food and Drug Administration (FDA) clearance in a broad range of solid tumors including ovarian, colorectal, and prostate. Introducing SC to eligible patients, including those distraught by concerns of CIA, requires an integrated effort on the part of the physician, nursing, and care manager medical team. This article presents a pragmatic workflow for collaborative efforts from physicians and allied health professionals in the USA to deliver supportive SC to reduce CIA in patients undergoing treatment regimens known to impact hair follicles. It further highlights the efforts required to identify appropriate patients, educate, and set expectations of patients. The supervisory role of the physician during the procedure, the nursing role in monitoring and documentation, and the post-procedure decision-making by the physician are also addressed. Lastly, it suggests that integrated physician and nursing efforts necessary for scalp cooling are similar to other care used in oncology.

show abstract

Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study

Cited by 24 publications

References 19 publications

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Scalp Cooling Impact in Alopecia of Patients Under Treatment for Breast Cancer—Literature Review

Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for Alopecia

Contact Info

Product

Resources

About